Ovid Therapeutics Inc. (1OT.F)
| Previous Close | 2.9800 |
| Open | 2.9800 |
| Bid | 2.9600 x 0 |
| Ask | 3.0400 x 0 |
| Day's Range | 2.9800 - 2.9800 |
| 52 Week Range | 2.4600 - 3.6800 |
| Volume | |
| Avg. Volume | 16 |
| Market Cap | 213.842M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings Date | May 03, 2024 - May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
GlobeNewswireOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET. A live webcast of the Needham presentation can be accessed through the Events & Presentations section of
Simply Wall St.Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying
Last week, Ovid Therapeutics Inc. ( NASDAQ:OVID ) insiders, who had purchased shares in the previous 12 months were...
- GlobeNewswire
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024OV888 (GV101) is progressing on-track in a Phase 1, double-blind, multiple-ascending dose trial; a higher dose cohort has been added and no serious adverse events have been observed Feedback from a pre-IND session with the FDA supports potential initiation of a Phase 2 study of O
